Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Authors
Keywords
-
Journal
mAbs
Volume 5, Issue 6, Pages 826-837
Publisher
Informa UK Limited
Online
2013-08-09
DOI
10.4161/mabs.26008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
- (2013) Miroslav Dostalek et al. CLINICAL PHARMACOKINETICS
- At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity
- (2013) Anne Danielou-Lazareth et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
- (2013) David Cunningham et al. LANCET
- Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
- (2013) Richard Delarue et al. LANCET ONCOLOGY
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
- (2013) Sally Wenzel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isotype and glycoform selection for antibody therapeutics
- (2012) Roy Jefferis ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
- (2012) M. S. Czuczman et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
- (2012) C. Muller et al. BLOOD
- Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
- (2012) J. L. Rubenstein et al. BLOOD
- Properties of mouse and human IgG receptors and their contribution to disease models
- (2012) P. Bruhns BLOOD
- Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics
- (2012) J. M. Harrold et al. CANCER RESEARCH
- A Guide to Rational Dosing of Monoclonal Antibodies
- (2012) Shuang Bai et al. CLINICAL PHARMACOKINETICS
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response
- (2012) U. Jager et al. HAEMATOLOGICA
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
- (2012) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia
- (2012) Jing Li et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Novel CD20 monoclonal antibodies for lymphoma therapy
- (2012) Shundong Cang et al. Journal of Hematology & Oncology
- Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
- (2012) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
- (2012) F. J. Beurskens et al. JOURNAL OF IMMUNOLOGY
- Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study
- (2012) Angelo M. Carella et al. LEUKEMIA & LYMPHOMA
- Lepidopteran cells, an alternative for the production of recombinant antibodies?
- (2012) Martine Cérutti et al. mAbs
- Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice
- (2012) Rong Deng et al. mAbs
- Setting the stage for biosimilar monoclonal antibodies
- (2012) Christian K Schneider et al. NATURE BIOTECHNOLOGY
- Monoclonal antibody (mAb)-based cancer therapy
- (2012) Margaret A. Lindorfer et al. OncoImmunology
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- The impact of Fc- receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
- (2011) M. Ahlgrimm et al. BLOOD
- Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma
- (2011) David Ternant et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
- (2011) G. Cartron et al. CLINICAL CANCER RESEARCH
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells
- (2011) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Monoclonal antibodies in neuro-oncology
- (2011) Lois A. Lampson mAbs
- Neonatal Fc receptor and IgG-based therapeutics
- (2011) Timothy T. Kuo et al. mAbs
- Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats
- (2011) Leonid Kagan et al. PHARMACEUTICAL RESEARCH
- Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death
- (2010) J. Golay et al. BLOOD
- Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation
- (2010) H. Yokoyama et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- Rituximab
- (2010) Gillian M. Keating DRUGS
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
- (2010) Stephen A. Beers et al. SEMINARS IN HEMATOLOGY
- In vivo Model of Follicular Lymphoma Resistant to Rituximab
- (2009) S. Dalle et al. CLINICAL CANCER RESEARCH
- Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
- (2009) PY Muller et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Novel targeted therapies for autoimmunity
- (2009) E William St Clair CURRENT OPINION IN IMMUNOLOGY
- Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
- (2009) G. Aue et al. HAEMATOLOGICA
- Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
- (2009) Diane D. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
- (2009) M. Leidi et al. JOURNAL OF IMMUNOLOGY
- Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
- (2009) A. W. Pawluczkowycz et al. JOURNAL OF IMMUNOLOGY
- Structural Difference in the Complement Activation Site of Human IgG1 and IgG3
- (2009) T. E. Michaelsen et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
- (2009) Royston Jefferis TRENDS IN PHARMACOLOGICAL SCIENCES
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- (2008) E C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies
- (2008) Julien Lejeune et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More